As per DelveInsight, in 2017, the total prevalent population of Adrenoleukodystrophy in the 7MM was 55,242.
A higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries during the study period (2017–2030).
The market size for Adrenoleukodystrophy in the United States was USD 523.26 million in 2017. The market of Adrenoleukodystrophy is expected to experience a significant rise in the coming years.
Increased number of potential therapies in the pipeline, awareness about newborn screening programs, increased in the number of childhood cerebral Adrenoleukodystrophy cases are some of the key factors expected to drive the Adrenoleukodystrophy Market in the upcoming years.
The key players in the Adrenoleukodystrophy Market include Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris, SOM Biotech and others.
For more information visit:
https://www.delveinsight.com/report-store/adrenoleukodystrophy-market